Protara Highlights Strong Phase 2 Data for TARA-002

Protara Therapeutics ( (TARA) ) has shared an announcement.

On February 23, 2026, Protara Therapeutics reported updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial of intravesical TARA-002 in high-risk non-muscle invasive bladder cancer with carcinoma in situ in patients who are BCG-unresponsive or BCG-naïve. The data, with a cutoff of January 28, 2026 and to be presented on February 27, 2026 at the ASCO Genitourinary Cancers Symposium, showed robust complete response rates and durability in both cohorts.

In the BCG-unresponsive cohort, TARA-002 achieved a complete response at any time in 65.7% of evaluable patients, with a 68.2% complete response rate at six months and indications of sustained responses through 12 months among those followed. In the BCG-naïve cohort, the complete response rate at any time reached 72.4%, with 66.7% at six months and 57.9% at 12 months, and re-induction converted a majority of initial non-responders in both groups.

Safety data showed a favorable tolerability profile, with most treatment-related adverse events being transient Grade 1 bladder and systemic symptoms, no Grade 3 or higher treatment-related events, no related serious adverse events, and no discontinuations due to toxicity. These results, coupled with streamlined intravesical administration, underscore TARA-002’s potential to become a meaningful addition to the non-muscle invasive bladder cancer treatment landscape and strengthen Protara’s clinical and commercial positioning.

Operationally, Protara indicated it expects to complete enrollment of the BCG-unresponsive registrational cohort of ADVANCED-2 in the second half of 2026, while enrollment in the BCG-naïve cohort is already complete with 31 patients. The company also plans to initiate the ADVANCED-3 registrational trial in BCG-naïve patients in the second half of 2026, signaling a clear path toward potential registration and heightening expectations among investors and clinicians monitoring this program.

The most recent analyst rating on (TARA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.

Spark’s Take on TARA Stock

According to Spark, TipRanks’ AI Analyst, TARA is a Neutral.

The score is held back primarily by weak financial performance—no revenue, sizable losses, and heavy cash burn—despite a strong, low-debt balance sheet. Offsetting this, the stock shows strong technical momentum (though overbought) and recent positive clinical and financing events that improve near-term runway and program credibility. Valuation contributes little support due to negative earnings and no dividend.

To see Spark’s full report on TARA stock, click here.

More about Protara Therapeutics

Protara Therapeutics, Inc. is a New York-based clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases. Its lead candidate, TARA-002, is an investigational cell-based therapy in development for non-muscle invasive bladder cancer and lymphatic malformations, alongside an IV choline chloride program for patients on parenteral nutrition.

The company is targeting high-risk non-muscle invasive bladder cancer, particularly patients who are Bacillus Calmette-Guérin unresponsive or naïve, positioning itself in a segment with significant unmet medical need. By advancing TARA-002 through mid-stage clinical trials and preparing registrational studies, Protara is aiming to secure a foothold in the uro-oncology market.

Average Trading Volume: 995,052

Technical Sentiment Signal: Buy

Current Market Cap: $344.4M

See more data about TARA stock on TipRanks’ Stock Analysis page.